摘要
Abstract
Objective:To Objective To investigate the efficacy of irbesartan combined with mycophenolate mofetil in the treatment of lupus nephritis(LN)and its influence on urinary biomarkers.Methods:From January 2016 to De-cember 2018,89 patients with LN who were treated in the Department of Nephrology,Wuxi Second Hospital affili-ated to Nanjing Medical University were randomly divided into control group(43 cases)and experimental group(46 cases).Both groups were given standard hormone therapy,the control group was treated with irbesartan combined with cyclophosphamide,and the experimental group was treated with mycophenolate mofetil combined with irbe-sartan on the basis of the control group.Both groups continued to be treated for 6 months,and the therapeutic effect and the level of urinary biomarkers were compared.Results:The total effective rate in the experimental group was higher than that in the control group,P＜0.05.After treatment,the urine biomarkers、24-hour urine protein quantification、Scr and BUN levels in the experimental group were lower than those in the control group,P＜0.05.The incidence of adverse reactions between the two groups was compared,P＞0.05.Conclusion:Irbesartan combined with mycophenolate mofetil can improve the therapeutic effect of LN,reduce the level of urinary biomark-ers,and have good drug safety.关键词
厄贝沙坦/霉酚酸酯/狼疮性肾炎/尿液生物学标记物Key words
Irbesartan/Mycophenolate mofetil/Lupus nephritis/Urine biological marker分类
医药卫生
